DocLab Inc.
FDA 510(k) & De Novo Consulting for Medical Device Startups | DocLab Inc.
DocLab Inc. is a dedicated FDA regulatory consulting firm with 12 years of experience, specializing in guiding startups through the 510(k) and De Novo pathways. They offer expert services to help medical device companies achieve successful FDA clearances, with a particular focus on Software as a Medical Device (SaMD) for Class I and Class II devices.
About
DocLab Inc. is a dedicated FDA regulatory consulting firm with 12 years of experience, specializing in guiding startups through the 510(k) and De Novo pathways. They offer expert services to help medical device companies achieve successful FDA clearances, with a particular focus on Software as a Medical Device (SaMD) for Class I and Class II devices.
Additional information
### **Additional information**
- **Type:** firm
- **Company:** DocLab Inc.
- **Years of experience:** 12
- **Client types:** startup
- **Location:** United States
- **Availability:** available_now
### **Cruxi analysis**
- **Strength summary:** DocLab Inc. offers a highly specialized and valuable service for medical device startups, leveraging 12 years of focused experience in FDA 510(k) and De Novo regulatory pathways. Their unique strength lies in guiding early-stage companies through the complexities of Class I and Class II device clearances, with a distinct expertise in Software as a Medical Device (SaMD). This deep niche focus, combined with a fixed-project pricing structure, provides predictability and tailored support for innovative companies bringing digital health solutions to market.
- **Unique value:** DocLab Inc.'s key differentiator is their hyper-specialized focus on 510(k) and De Novo pathways specifically for startups developing Class I/II Software as a Medical Device (SaMD), offering targeted expertise and predictable project pricing.
- **Ideal projects:** The ideal client for DocLab Inc. is a medical device startup developing a Class I or Class II device, particularly one involving Software as a Medical Device (SaMD). These clients are typically seeking initial FDA clearance via either the traditional 510(k) or De Novo pathway and require expert navigation through these specific regulatory processes. Projects best suited for DocLab Inc. involve companies that need hands-on guidance from concept to successful clearance, valuing a consultant with a proven track record in these specialized areas and a predictable fixed-project fee structure.
- **Confidence score:** 70/100
- **Last analyzed:** Sun Dec 14 2025 01:15:47 GMT-0500 (Eastern Standard Time)
### **Qualifications & scope**
- **Submission types:** 510k-traditional, de-novo
- **Device classes:** class-i, class-ii
- **Specialties:** software-samd
- **Regulatory pathways:** 510k, de_novo
- **Type:** firm
- **Company:** DocLab Inc.
- **Years of experience:** 12
- **Client types:** startup
- **Location:** United States
- **Availability:** available_now
### **Cruxi analysis**
- **Strength summary:** DocLab Inc. offers a highly specialized and valuable service for medical device startups, leveraging 12 years of focused experience in FDA 510(k) and De Novo regulatory pathways. Their unique strength lies in guiding early-stage companies through the complexities of Class I and Class II device clearances, with a distinct expertise in Software as a Medical Device (SaMD). This deep niche focus, combined with a fixed-project pricing structure, provides predictability and tailored support for innovative companies bringing digital health solutions to market.
- **Unique value:** DocLab Inc.'s key differentiator is their hyper-specialized focus on 510(k) and De Novo pathways specifically for startups developing Class I/II Software as a Medical Device (SaMD), offering targeted expertise and predictable project pricing.
- **Ideal projects:** The ideal client for DocLab Inc. is a medical device startup developing a Class I or Class II device, particularly one involving Software as a Medical Device (SaMD). These clients are typically seeking initial FDA clearance via either the traditional 510(k) or De Novo pathway and require expert navigation through these specific regulatory processes. Projects best suited for DocLab Inc. involve companies that need hands-on guidance from concept to successful clearance, valuing a consultant with a proven track record in these specialized areas and a predictable fixed-project fee structure.
- **Confidence score:** 70/100
- **Last analyzed:** Sun Dec 14 2025 01:15:47 GMT-0500 (Eastern Standard Time)
### **Qualifications & scope**
- **Submission types:** 510k-traditional, de-novo
- **Device classes:** class-i, class-ii
- **Specialties:** software-samd
- **Regulatory pathways:** 510k, de_novo
Key Highlights
- DocLab Inc. offers a highly specialized and valuable service for medical device startups, leveraging 12 years of focused experience in FDA 510(k) and De Novo regulatory pathways. Their unique strength lies in guiding early-stage companies through the complexities of Class I and Class II device clearances, with a distinct expertise in Software as a Medical Device (SaMD). This deep niche focus, combined with a fixed-project pricing structure, provides predictability and tailored support for innova
- DocLab Inc.'s key differentiator is their hyper-specialized focus on 510(k) and De Novo pathways specifically for startups developing Class I/II Software as a Medical Device (SaMD), offering targeted expertise and predictable project pricing.
Certifications & Trust Signals
- 12 years experience
Buyer Snapshot
Best for
- The ideal client for DocLab Inc. is a medical device startup developing a Class I or Class II device, particularly one involving Software as a Medical Device (SaMD). These clients are typically seeking initial FDA clearance via either the traditional 510(k) or De Novo pathway and require expert navigation through these specific regulatory processes. Projects best suited for DocLab Inc. involve com
HQ:
United States
Languages:
English
Status:
listed
Services & Capabilities
FDA 510(k) Submission Services
Jurisdictions:
US
Services Offered:
Regulatory Pathway Assessment, Device Classification Support, Predicate Research & Substantial Equivalence Strategy, De Novo Strategy & Authoring, PMA Strategy & Support
Pathways Supported:
Traditional 510(k), De Novo
Device Types Supported:
SaMD, Medical device
Supports Predicate Research:
Yes
Years Experience:
12
Ex FDA:
No
Ex Notified Body:
No
Ex Big Medtech:
No
Engagement Models:
fixed_fee
Accepting New Clients:
No
